The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Michael Wolff believes that Pete Hegseth’s lack of experience for the role of Defense Secretary is proving to be a boon to President Donald Trump. Reporter President Donald Trump’s “shameful” bombings ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. If you close one eye or put a finger to your ear, there’s an ...

One analyst tracking the biotech upgraded her recommendation on its shares. She now believes that they rate a buy, rather than a hold. 10 stocks we like better than Recursion Pharmaceuticals › An ...